

OMB Control Number:

Expiration Date:

**DEFENSE INDUSTRIAL BASE ASSESSMENT:
Healthcare and Public Health (HPH) Sector
Survey for Manufacturers**



SCOPE OF ASSESSMENT

The U.S. Department of Commerce, Bureau of Industry and Security (BIS), Office of Technology Evaluation (OTE), in coordination with the Department of Homeland Security (DHS), is conducting an assessment regarding the supply chain within the Healthcare and Public Health (HPH) sector. The principal goal of this assessment is to identify foreign sourcing, critical dependencies and other supply chain issues that could have a negative impact on the delivery of effective medical services in the United States.

RESPONSE TO THIS SURVEY IS REQUIRED BY LAW

A response to this survey is required by law (50 U.S.C. app. Sec. 2155). Failure to respond can result in a maximum fine of \$10,000, imprisonment of up to one year, or both. Information furnished herewith is deemed confidential and will not be published or disclosed except in accordance with Section 705 of the Defense Production Act of 1950, as amended (50 U.S.C App. Sec. 2155). Section 705 prohibits the publication or disclosure of this information unless the President determines that its withholding is contrary to the national defense. Information will not be shared with any non-government entity, other than in aggregate form. The information will be protected pursuant to the appropriate exemptions from disclosure under the Freedom of Information Act (FOIA), should it be the subject of a FOIA request.

Notwithstanding any other provision of law, no person is required to respond to nor shall a person be subject to a penalty for failure to comply with a collection of information subject to the requirements of the Paperwork Reduction Act unless that collection of information displays a currently valid OMB Control Number.

BURDEN ESTIMATE AND REQUEST FOR COMMENT

Public reporting burden for this collection of information is estimated to average 13 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information to BIS Information Collection Officer, Room 6883, Bureau of Industry and Security, U.S. Department of Commerce, Washington, D.C. 20230, and to the Office of Management and Budget, Paperwork Reduction Project (**OMB Control No.**), Washington, D.C. 20503.

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section I	General Instructions
A.	Your company is required to complete this survey using an Excel template, which can be downloaded from the BIS website. At your request, BIS staff will e-mail the Excel survey template directly to your company. For your convenience, a PDF version of the survey is available on the BIS website to aid internal data collection. PLEASE DO NOT submit the PDF version of your company's response to BIS.
B.	If information is not available from your records in the form requested, you may furnish estimates. Please indicate in the comment box on the page when you use an estimate.
C.	<p>Questions related to this survey should be directed to:</p> <p>Anna Bruse, Trade and Industry Analyst, (202) 482-7418 Erika Maynard, Trade and Industry Analyst, (202) 482-5572 Michael Finucane, Trade and Industry Analyst, (202) 482-3893</p>
D.	Upon completion, review and certification of the survey, transmit the survey via e-mail to CFDHealthcare@bis.doc.gov .
E.	<p>For letter correspondence to the Office of Technology Evaluation (OTE), please write to:</p> <p>Brad Botwin, Director, Industrial Studies Office of Technology Evaluation, Room 1093 U.S. Department of Commerce 1401 Constitution Avenue, NW Washington, DC 20230</p> <p>Please do not submit completed surveys to this address; all surveys must be submitted electronically.</p>
BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act	

Section II		Who Must Respond	
A.	Has your company manufactured or integrated/assembled healthcare-related pharmaceutical, equipment, or device products between 2007-2010?		
B.	Identify the general product areas your company manufactures or integrates/assembles from the list below, as applicable.		
	Anaesthetics		Cancer Treatments
	Analgesics		Cardiovasculars
	Antibacterials		Hormones
	Antibiotics		Immunosuppressants
	Anticonvulsants, Sedatives, Relaxants		Stimulants
	Anti-Inflammatories		Vaccines
	Antileprosy		Surgical and Medical Instruments
	Antiprotozoals		Medical Devices
	Antivirals		
C.	Does your company also manufacture or integrate/assemble non-healthcare related pharmaceutical, equipment, or device products?		
	If 'Yes,' indicate the percentage of your business that is not related to healthcare pharmaceutical, equipment, or device products:		
Exemption From Survey			
If you answered "No" to Question B above, you may be exempt from completing this U.S. Government survey. Please review the products identified in the Critical Commodities List (Sections 2.a through 2.h on this survey). If your company does not manufacture any of these products, complete Section 1.c and call one of the BIS contacts listed on the previous page.			
Comments:			
BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act			

Section III	Definitions
Alternate Source	A supplier of the same product or an alternative product that, in the opinion of experts qualified by scientific training and experience to evaluate the safety and effectiveness of pharmaceuticals and/or medical devices, it is prudent to assume or ascertain the liability of similar side effects and contraindications.
Component	Any raw material, substance, piece, part, software, firmware, labeling, or assembly which is intended to be included as part of the finished, packaged, and labeled device.
Disruption Clauses	Contract provisions that impose penalties on suppliers to recoup losses in the advent of a delivery/service delay or interruption.
Finished Product	Any device, accessory to any device, or drug product, that is suitable for use or capable of functioning, whether or not it is packaged, labeled, or sterilized.
Manufacturing Material	Any material or substance used in or used to facilitate the manufacturing process, a concomitant constituent, or a byproduct constituent produced during the manufacturing process, which is present in or on the finished device/product as a residue or impurity not by design or intent of the manufacturer.
Sole Source/Sole Manufacturer	A supplier that is the only manufacturer or distributor of a product. For this product, there are either 1) no alternate products or 2) potential alternate products have substantially different levels of effectiveness and/or potential side effects.
Surge Capacity Provisions	Contract provisions that allow the contracting party to a) increase the quantity of products or services called for under the contract by a certain amount; and/or b) accelerate the rate of delivery established under the contract.
BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act	

Section 1.a					Company Information			
A.	Company Name							
	Street Address							
	City							
	State							
	Zip Code							
	Phone Number							
	Fax Number							
	Website							
B.	Point of Contact(s) regarding this survey:							
	Name	Title	E-mail	Phone Number				
Comments:								
BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act								

Section 1.b Company Ownership Information							
A.	My company is headquartered in:						
	My company is:						
	Parent Company Name	Address		City	State/Province	Country	
	My company is Public/Private:						
My parent company is Public/Private:							
B.	Please identify the entities and/or individuals currently holding 5 percent or more of your company's or organization's voting rights. List no more than 5, if applicable, and place them in descending order, the highest percentage stake listed first. This question applies to both public and privately held companies.						
		Entity or Individual's Name	Stake (%)	Address	City	State/Province	Country
	1.						
	2.						
	3.						
	4.						
	5.						
C.	From 2007-2010, has one or more foreign governments invested, directly or indirectly, in your company and control 5 percent or more of stockholder voting shares?						
	If you answered "Yes," please explain the type of investment and identify the foreign government(s).						
		Type of Investment		Foreign Government			
	1.						
	2.						
	3.						
4.							
5.							
Comments:							
BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act							

Section 1.c

Manufacturing Facilities

Identify the facilities your company owns and operates **in the United States** for the manufacture or integration/assembly of healthcare-related pharmaceutical, equipment, or device products. Provide the name and location for each facility.

A.	ID #	Facility Name	Street Address	City	State	Zip Code
	US - 1					
	US - 2					
	US - 3					
	US - 4					
	US - 5					
	US - 6					
	US - 7					
	US - 8					
	US - 9					
	US - 10					
	US - 11					
	US - 12					
	US - 13					
	US - 14					
	US - 15					

Identify the facilities your company owns and operates **outside the United States** for the manufacture or integration/assembly of healthcare-related pharmaceutical, equipment, or device products. Provide the name and location for each facility.

B.	ID #	Facility Name	Street Address	City	State/Province	Country
	Non-US - 1					
	Non-US - 2					
	Non-US - 3					
	Non-US - 4					
	Non-US - 5					
	Non-US - 6					
	Non-US - 7					
	Non-US - 8					
	Non-US - 9					
	Non-US - 10					
	Non-US - 11					
	Non-US - 12					
	Non-US - 13					
	Non-US - 14					
	Non-US - 15					

Comments:

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 2.a Critical Commodities List

From the product areas listed below, indicate those that your company currently manufactures or integrates/assembles. For each area, identify the top three discrete products (by an estimate of annual sales) your company currently produces and whether your company, to the best of your knowledge, is the sole U.S.-based manufacturer, sole global manufacturer, or not a sole manufacturer of this product. If you are not sure, select "Not Sure" from the drop-down box. Finally, indicate the primary manufacturing facility in which each product is produced (the facility that adds the most value to the finished product) based on those identified in Section 1.c.

Differentiate products based on their unique effects or capabilities. Do not differentiate products based solely on dosage, strength, or method of delivery.

Note: If the product you manufacture does not fit the product area exactly (e.g. it is a combination of multiple product areas, your company classifies its product under a similar, but different area, etc.) make note of this in the comments area in the far right column.

Note: For the purposes of this survey a sole manufacturer is the only manufacturer of a product of a particular use, capability, or function. For this product, there are either 1) no alternate products or 2) potential alternate products have substantially different levels of effectiveness and/or potential side effects.

Anaesthetics											
Product Area	Manufacture?	1			2			3			Product Area Comments
		Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
A1 Atropine/Atropine Sulfate											
A2 Bupivacaine											
A3 Halothane											
A4 Ketamine											
A5 Lidocaine											
A6 Nitrous Oxide											
A7 Pancuronium Bromide											
A8 Promethazine											
A9 Propofol											
A10 Thiopental/Pentothal											
A11 Thiopentone Sodium											
Analgesics											
Product Area	Manufacture?	1			2			3			Product Area Comments
		Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
B1 Acetylsalicylic Acid (Aspirin)											
B2 Allopurinol											
B3 Aminophenazone											
B4 Azathioprine											
B5 Buprenorphine											
B6 Carbamazepine											
B7 Chloroquine											
B8 Cinchonine											
B9 Codeine											
B10 Dihydrocodeine											
B11 Etorphine											
B12 Hydrocodone											
B13 Hydromorphone											
B14 Ibuprofen											
B15 Levorphanol											
B16 Methotrexate											
B17 Morphine											
B18 Nicomorphine											
B19 Oxycodone											
B20 Oxymorphone											
B21 Paracetamol/Acetaminophen											
B22 Penicillamine											
B23 Pholcodine											
B24 Quinine											
B25 Thebacon											
Antibacterials											
Product Area	Manufacture?	1			2			3			Product Area Comments
		Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
C1 Furazolidone											
C2 Sulfamerazine											

C3 Sulphadiazine												
C4 Sulphapyridine												
C5 Sulphathiazole												
C6 Sulphathiourea												
Comments:												
BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act												

Section 2.b Critical Commodities List

From the product areas listed below, indicate those that your company currently manufactures or integrates/assembles. For each area, identify the top three discrete products (by an estimate of annual sales) your company currently produces and whether your company, to the best of your knowledge, is the sole U.S.-based manufacturer, sole global manufacturer, or not a sole manufacturer of this product. If you are not sure, select "Not Sure" from the drop-down box. Finally, indicate the primary manufacturing facility in which each product is produced (the facility that adds the most value to the finished product) based on those identified in Section 1.c.

Differentiate products based on their unique effects or capabilities. Do not differentiate products based solely on dosage, strength, or method of delivery.

Note: If the product you manufacture does not fit the product area exactly (e.g. it is a combination of multiple product areas, your company classifies its product under a similar, but different area, etc.) make note of this in the comments area in the far right column.

Note: For the purposes of this survey a sole manufacturer is the only manufacturer of a product of a particular use, capability, or function. For this product, there are either 1) no alternate products or 2) potential alternate products have substantially different levels of effectiveness and/or potential side effects.

Product Area	Manufacture?	1			2			3			Product Area Comments
		Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
D1 Actinomycins											
D2 Amoxicillin											
D3 Ampicillin											
D4 Azithromycin											
D5 Aztreonam											
D6 Bacitracin											
D7 Benzylpenicillin (Penicillin G)											
D8 Cefalexin											
D9 Cefazolin											
D10 Cefixime											
D11 Cefotaxime											
D12 Ceftriaxone											
D13 Ceftriaxone											
D14 Chloramphenicol											
D15 Ciprofloxacin											
D16 Clarithromycin											
D17 Clindamycin											
D18 Cloxacillin											
D19 Doripenem											
D20 Doxycycline											
D21 Erythromycin											
D22 Gentamicin											
D23 Gramicidines											
D24 Imipenem											
D25 Levofloxacin											
D26 Metronidazole											
D27 Minocycline											
D28 Nitrofurantoin											
D29 Phenoxymethylpenicillin											
D30 Procaine Benzylpenicillin											
D31 Sarkomycin											
D32 Spectinomycin											
D33 Streptomycin											
D34 Talampicillin											
D35 Tetracycline											
D36 Thiamphenicol											
D37 Trimethoprim											
D38 Tyrocidin											
D39 Vancomycin											
D40 Zanamivir											

Comments:

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 2.c Critical Commodities List

From the product areas listed below, indicate those that your company currently manufactures or integrates/assembles. For each area, identify the top three discrete products (by an estimate of annual sales) your company currently produces and whether your company, to the best of your knowledge, is the sole U.S.-based manufacturer, sole global manufacturer, or not a sole manufacturer of this product. If you are not sure, select "Not Sure" from the drop-down box. Finally, indicate the primary manufacturing facility in which each product is produced (the facility that adds the most value to the finished product) based on those identified in Section 1.c.

Differentiate products based on their unique effects or capabilities. Do not differentiate products based solely on dosage, strength, or method of delivery.

Note: If the product you manufacture does not fit the product area exactly (e.g. it is a combination of multiple product areas, your company classifies its product under a similar, but different area, etc.) make note of this in the comments area in the far right column.

Note: For the purposes of this survey a sole manufacturer is the only manufacturer of a product of a particular use, capability, or function. For this product, there are either 1) no alternate products or 2) potential alternate products have substantially different levels of effectiveness and/or potential side effects.

Anticonvulsants, Sedatives, Relaxants											
Product Area	Manufacture?	1			2			3			Product Area Comments
		Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
E1 Alprazolam											
E2 Atracurium Besylate											
E3 Camazepam											
E4 Chlordiazepoxide											
E5 Clonazepam											
E6 Clorazepate											
E7 Delorazepam											
E8 Diazepam											
E9 Estazolam											
E10 Ethosuximide											
E11 Ethyl Loflazepate											
E12 Fludiazepam											
E13 Flunitrazepam											
E14 Flurazepam											
E15 Halazepam											
E16 Lorazepam											
E17 Lormetazepam											
E18 Mazindol											
E19 Medazepam											
E20 Midazolam											
E21 Nimetazepam											
E22 Nitrazepam											
E23 Nordazepam											
E24 Oxazepam											
E25 Phenobarbital											
E26 Phenytoin											
E27 Pinazepam											
E28 Pralidoxime/Pralidoxime Chloride											
E29 Prazepam											
E30 Pyrovalerone											
E31 Temazepam											
E32 Tetrazepam											
E33 Triazolam											
E34 Valproic Acid (VPA)											
E35 Vecuronium Bromide											
Anti-Inflammatories											
Product Area	Manufacture?	1			2			3			Product Area Comments
		Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
F1 Dexamthasone											
F2 Flucinolone Acetonide											
F3 Indometacin/Indomethacin											
F4 Rutoside/Rutin											
F5 Tolmetin											
Comments:											

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 2.d Critical Commodities List

From the product areas listed below, indicate those that your company currently manufactures or integrates/assembles. For each area, identify the top three discrete products (by an estimate of annual sales) your company currently produces and whether your company, to the best of your knowledge, is the sole U.S.-based manufacturer, sole global manufacturer, or not a sole manufacturer of this product. If you are not sure, select "Not Sure" from the drop-down box. Finally, indicate the primary manufacturing facility in which each product is produced (the facility that adds the most value to the finished product) based on those identified in Section 1.c.

Differentiate products based on their unique effects or capabilities. Do not differentiate products based solely on dosage, strength, or method of delivery.

Note: If the product you manufacture does not fit the product area exactly (e.g. it is a combination of multiple product areas, your company classifies its product under a similar, but different area, etc.) make note of this in the comments area in the far right column.

Note: For the purposes of this survey a sole manufacturer is the only manufacturer of a product of a particular use, capability, or function. For this product, there are either 1) no alternate products or 2) potential alternate products have substantially different levels of effectiveness and/or potential side effects.

Antileprosy											
Product Area	Manufacture?	1			2			3			Product Area Comments
		Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
G1 Amikacin											
G2 Capreomycin											
G3 Clofazimine											
G4 Cycloserine											
G5 Dapsone											
G6 Ethambutol											
G7 Ethionamide											
G8 Isoniazid											
G9 Kanamycin											
G10 Ofloxacin											
G11 P-Aminosalicylic Acid											
G12 Pyrazinamide											
G13 Rifabutin											
G14 Rifampicin/Rifampin											
Antiprotozoals											
Product Area	Manufacture?	1			2			3			Product Area Comments
		Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
H1 Amodiaquine											
H2 Artemether											
H3 Benznidazole											
H4 Diloxanide											
H5 Eflornithine											
H6 Mefloquine											
H7 Nicarbazin											
H8 Nifurtimox											
H9 Paramomycin											
H10 Pentamidine											
H11 Primaquine											
H12 Proguanil											
H13 Pyrimethamine											
Antivirals											
Product Area	Manufacture?	1			2			3			Product Area Comments
		Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
I1 Abacavir (ABC)											
I2 Acyclovir											
I3 Amantadine											
I4 Atazanavir											
I5 Cidofovir											
I6 Didanosine (ddl)											
I7 Efavirenz (EFV or EFZ)											
I8 Indinavir (DIV)											
I9 Lamivudine (3TC)											
I10 Nevirapine (NVP)											
I11 Oseltamivir (aka Tamiflu)											
I12 Ribavirin											

I13 Rimantadine												
I14 Ritonavir												
I15 Saquinavir (SQV)												
I16 Stavudine (d4T)												
I17 Tenofovir Disoproxil Fumarate (TDF)												
I18 Zidovudine (ZDV or AZT)												
Comments:												
BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act												

Section 2.e Critical Commodities List

From the product areas listed below, indicate those that your company currently manufactures or integrates/assembles. For each area, identify the top three discrete products (by an estimate of annual sales) your company currently produces and whether your company, to the best of your knowledge, is the sole U.S.-based manufacturer, sole global manufacturer, or not a sole manufacturer of this product. If you are not sure, select "Not Sure" from the drop-down box. Finally, indicate the primary manufacturing facility in which each product is produced (the facility that adds the most value to the finished product) based on those identified in Section 1.c.

Differentiate products based on their unique effects or capabilities. Do not differentiate products based solely on dosage, strength, or method of delivery.

Note: If the product you manufacture does not fit the product area exactly (e.g. it is a combination of multiple product areas, your company classifies its product under a similar, but different area, etc.) make note of this in the comments area in the far right column.

Note: For the purposes of this survey a sole manufacturer is the only manufacturer of a product of a particular use, capability, or function. For this product, there are either 1) no alternate products or 2) potential alternate products have substantially different levels of effectiveness and/or potential side effects.

Cancer Treatments											
Product Area	Manufacture?	1			2			3			Product Area Comments
		Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
J1 Folinic Acid/Leucovorin											
J2 Thiotepa											
J3 Valrubicin											
J4 Vinblastine Sulfate											
Cardiovasculars											
Product Area	Manufacture?	1			2			3			Product Area Comments
		Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
K1 Amiodarone											
K2 Amlodipine											
K3 Amolol											
K4 Atenolol											
K5 Digoxin											
K6 Dopamine											
K7 Enalapril											
K8 Furosemide											
K9 Glyceril Trinitrate											
K10 Hydralazine Hydrochloride											
K11 Hydrochlorothiazide											
K12 Isosorbide Dinitrate											
K13 Mexiletine											
K14 Sarpogrelate											
K15 Simvastatin											
K16 Streptokinase											
K17 Verapamil											
Hormones											
Product Area	Manufacture?	1			2			3			Product Area Comments
		Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
L1 Aglepristone											
L2 Estradiol											
L3 Estriol											
L4 Estrone											
L5 Ethinyl Estradiol											
L6 Fludrocortisone											
L7 Glibenclamide											
L8 Granulocyte-Colony Stimulating Factor (G-CSF)											
L9 Insulin											
L10 Levonorgestrel											
L11 Levothyroxine											
L12 Liothyronine											
L13 Medroxyprogesterone Acetate											
L14 Mestranol											
L15 Metformin											
L16 Norethisterone											
L17 Onapristone											

Section 2.f Critical Commodities List

From the product areas listed below, indicate those that your company currently manufactures or integrates/assembles. For each area, identify the top three discrete products (by an estimate of annual sales) your company currently produces and whether your company, to the best of your knowledge, is the sole U.S.-based manufacturer, sole global manufacturer, or not a sole manufacturer of this product. If you are not sure, select "Not Sure" from the drop-down box. Finally, indicate the primary manufacturing facility in which each product is produced (the facility that adds the most value to the finished product) based on those identified in Section 1.c.

Differentiate products based on their unique effects or capabilities. Do not differentiate products based solely on dosage, strength, or method of delivery.

Note: If the product you manufacture does not fit the product area exactly (e.g. it is a combination of multiple product areas, your company classifies its product under a similar, but different area, etc.) make note of this in the comments area in the far right column.

Note: For the purposes of this survey a sole manufacturer is the only manufacturer of a product of a particular use, capability, or function. For this product, there are either 1) no alternate products or 2) potential alternate products have substantially different levels of effectiveness and/or potential side effects.

Immunosuppressants											
Product Area	Manufacture?	1			2			3			Product Area Comments
		Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
M1 Aldosterone											
M2 Asparaginase											
M3 Bleomycin											
M4 Calcium Folate											
M5 Carboplatin											
M6 Chlorambucil											
M7 Cyclosporin											
M8 Cortisone											
M9 Cortodoxone											
M10 Cyclophosphamide											
M11 Cytarabine											
M12 Dactinomycin											
M13 Dacarbazine											
M14 Daunorubicin											
M15 Etoposide											
M16 Fluorouracil											
M17 Hydrocortisone											
M18 Hydrooxycarbamide											
M19 Ifosfamide											
M20 Mercaptopurine											
M21 Mesna											
M22 Prednisolone											
M23 Prednisone											
M24 Procarbazine											
M25 Tamoxifen											
M26 Vinblastine											
M27 Vincristine											
Stimulants											
Product Area	Manufacture?	1			2			3			Product Area Comments
		Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
N1 Aminorex											
N2 Brotizolam											
N3 Clotiazepam											
N4 Ephedrine											
N5 Epinephrine (Adrenaline)											
N6 Fenethylamine											
N7 Norepinephrine											
N8 Pseudoephedrine											
N9 Racepinephrine											
Vaccines											
Product Area	Manufacture?	1			2			3			Product Area Comments
		Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
O1 Anthrax Treatments (Immune Globulin Injection, Raxibacumab, etc.)											

O2	BCG Vaccine											
O3	Cholera Vaccine											
O4	Diphtheria Vaccine											
O5	Haemophilus Influenzae Type B Vaccine											
O6	Hepatitis A Vaccine											
O7	Hepatitis B Vaccine											
O8	Japanese Encephalitis Vaccine											
O9	Measles Vaccine											
O10	Meningococcal Meningitis Vaccine											
O11	Modified Vaccinia Ankara (MVA)											
O12	Mumps Vaccine											
O13	Pertussis Vaccine											
O14	Pneumococcal Vaccine											
O15	Poliomyelitis Vaccine											
O16	Rabies Vaccine											
O17	Rotavirus Vaccine											
O18	Rubella Vaccine											
O19	Smallpox Vaccine											
O20	Tetanus Vaccine											
O21	Typhoid Vaccine											
O22	Vaccinia Immune Globulin (VIG)											
O23	Varicella Vaccine											
O24	Yellow Fever Vaccine											

Other Products

Product Area	Manufacture?	1			2			3			Product Area Comments	
		Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility		
P1	Acridine											
P2	Botulinum Toxin(s)											
P3	Cyanide Treatments - Amyl Nitrate											
P4	Cyanide Treatments - Hydroxocobalamin											
P5	Cyanide Treatments - Sodium Nitrate											
P6	Cyanide Treatments - Sodium Thiosulfate											
P7	Diethylene Triamine Pentaacetic Acid (DTPA)/Pentetic Acid											
P8	Granisetron											
P9	Heparin											
P10	Imipramine											
P11	Lysine											
P12	Probenecid											
P13	Prussian Blue											
P14	Technetium Generators or other equipment for the processing of radioisotopes											
P15	Thioprop											

Comments:

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 2.g Critical Commodities List

From the product areas listed below, indicate those that your company currently manufactures or integrates/assembles. For each area, identify the top three discrete products (by an estimate of annual sales) your company currently produces and whether your company, to the best of your knowledge, is the sole U.S.-based manufacturer, sole global manufacturer, or not a sole manufacturer of this product. If you are not sure, select "Not Sure" from the drop-down box. Finally, indicate the primary manufacturing facility in which each product is produced (the facility that adds the most value to the finished product) based on those identified in Section 1.c.

Differentiate products based on their unique effects or capabilities. Do not differentiate products based solely on dosage, strength, or method of delivery.

Note: If the product you manufacture does not fit the product area exactly (e.g. it is a combination of multiple product areas, your company classifies its product under a similar, but different area, etc.) make note of this in the comments area in the far right column.

Note: For the purposes of this survey a sole manufacturer is the only manufacturer of a product of a particular use, capability, or function. For this product, there are either 1) no alternate products or 2) potential alternate products have substantially different levels of effectiveness and/or potential side effects.

Surgical and Medical Instruments											
Product Area	Manufacture?	1			2			3			Product Area Comments
		Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
Q1 Adhesive Dressings											
Q2 Aerosol Therapy Apparatus											
Q3 Anaesthesia Units											
Q4 Anaesthetic Apparatus											
Q5 Anti-Radiation Protective Suits											
Q6 Apnea Monitors											
Q7 Apparatus Based on Alpha, Beta, or Gamma Radiations for Medical Use											
Q8 Argon Enhanced Coagulation Units											
Q9 Artificial Kidney/Dialysis Apparatus											
Q10 Artificial Respiration Apparatus											
Q11 Aspirators											
Q12 Auriscopes											
Q13 Blood Collection Tubes											
Q14 Blood Pressure Measuring Equipment											
Q15 Blood Transfusion Apparatus											
Q16 Bone Nails and Screws											
Q17 Bone Plates											
Q18 Bronchoscopes											
Q19 Capnographs											
Q20 Cardioscopes											
Q21 IV Catheters											
Q22 Adult Central Venous Catheters											
Q23 Pediatric Central Venous Catheters											
Q24 Swan-Ganz Catheters											
Q25 Suction Catheters											
Q26 Other Catheters											
Q27 Cauteries											
Q28 Cephalometers											
Q29 Crutches											
Q30 Cutaneous Dressings											
Q31 Defibrillators											
Q32 Dilators											
Q33 Electrocardiographs											
Q34 Electroencephalographs (EEG)											
Q35 Electronic Nerve Stimulation Machines											
Q36 Electrosphygmographs											
Q37 Electrotonographs											
Q38 Endoscopes											
Q39 Endotracheal Tubes (adult and pediatric)											

Section 2.h Critical Commodities List

From the product areas listed below, indicate those that your company currently manufactures or integrates/assembles. For each area, identify the top three discrete products (by an estimate of annual sales) your company currently produces and whether your company, to the best of your knowledge, is the sole U.S.-based manufacturer, sole global manufacturer, or not a sole manufacturer of this product. If you are not sure, select 'Not Sure' from the drop-down box. Finally, indicate the primary manufacturing facility in which each product is produced (the facility that adds the most value to the finished product) based on those identified in Section 1.c.

Differentiate products based on their unique effects or capabilities. Do not differentiate products based solely on dosage, strength, or method of delivery.

Note: If the product you manufacture does not fit the product area exactly (e.g. it is a combination of multiple product areas, your company classifies its product under a similar, but different area, etc.) make note of this in the comments area in the far right column.

Note: For the purposes of this survey a sole manufacturer is the only manufacturer of a product of a particular use, capability, or function. For this product, there are either 1) no alternate products or 2) potential alternate products have substantially different levels of effectiveness and/or potential side effects.

Surgical and Medical Instruments (cont.)

Product Area	Manufacture?	1			2			3			Product Area Comments
		Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
Q70 Oropharyngeal Airway											
Q71 Oscillometers											
Q72 Oxygen Analyzers											
Q73 Oxygen Tents											
Q74 Oxygen Therapy Apparatus											
Q75 Ozone Therapy Apparatus											
Q76 Pacemakers											
Q77 Parts for Pacemakers											
Q78 Pelvimeters											
Q79 Phonocardiographs											
Q80 Protective Screens/Shields for X-Ray Facilities											
Q81 Pulse Oxymeters											
Q82 Pyrometers											
Q83 Radiotherapy Apparatus											
Q84 Respirators											
Q85 Respiratory Pumps and Filters											
Q86 Resuscitator Bag Valves and Masks											
Q87 Pulmonary Resuscitators											
Q88 Oxygen Resuscitators											
Q89 Retractors											
Q90 Rheocardiographs											
Q91 Saws and Scrapers for Medical Use											
Q92 Sissors and Shears for Medical Use											
Q93 Spatulae											
Q94 Specula											
Q95 Sphygmomanometers											
Q96 Spinal Needles											
Q97 Spirometers											
Q98 Splints											
Q99 Sterilizers											
Q100 Stethoscopes											
Q101 Stomach Pumps											
Q102 Suction Pumps											
Q103 Suction Tubes											
Q104 Surgical Gloves											
Q105 Surgical Gowns											
Q106 Surgical Knives and Scalpels											
Q107 Surgical Masks											
Q108 Surgical Staplers											
Q109 Suture Clips											
Q110 Sutures											
Q111 Tensiometers											
Q112 Thermometers											

Section 3.a

Critical Commodities - Non-U.S. Suppliers

Identify any components, manufacturing materials, or finished products **provided by suppliers based outside the United States** that are critical to the final manufacture of the products identified in the previous section. Indicate the product area and product name(s) for which this component/material is required and the supplier's name and location. In addition, indicate whether the component/material is supplied by an internal company supplier/subsidiary or is supplied by an outside company. Finally, identify, to the best of your company's understanding, whether there is an alternate U.S.-based or non-U.S. based source available for each component/material.

Note: If your company does not manufacture a product in a particular product area, you may leave it blank.

Anesthetics

	Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/Province	Internal Supplier/Subsidiary?	Alternate Source?
A. 1.									
2.									
3.									
4.									
5.									
6.									
7.									
8.									
9.									
10.									
11.									
12.									
13.									
14.									
15.									

Analgesics

	Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/Province	Internal Supplier/Subsidiary?	Alternate Source?
B. 1.									
2.									
3.									
4.									
5.									
6.									
7.									
8.									
9.									
10.									
11.									
12.									

13.									
14.									
15.									

Antibacterials

C.	Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/Province	Internal Supplier/Subsidiary?	Alternate Source?
	1.								
	2.								
	3.								
	4.								
	5.								
	6.								
	7.								
	8.								
	9.								
	10.								
	11.								
	12.								
	13.								
	14.								
	15.								

Antibiotics

D.	Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/Province	Internal Supplier/Subsidiary?	Alternate Source?
	1.								
	2.								
	3.								
	4.								
	5.								
	6.								
	7.								
	8.								
	9.								
	10.								
	11.								
	12.								
	13.								
	14.								
	15.								

Comments:

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 3.b Critical Commodities - Non-U.S. Suppliers

Identify any components, manufacturing materials, or finished products **provided by suppliers based outside the United States** that are critical to the final manufacture of the products identified in the previous section. Indicate the product area and product name(s) for which this component/material is required and the supplier's name and location. In addition, indicate whether the component/material is supplied by an internal company supplier/subsidiary or is supplied by an outside company. Finally, identify, to the best of your company's understanding, whether there is an alternate U.S.-based or non-U.S. based source available for each component/material.

Note: If your company does not manufacture a product in a particular product area, you may leave it blank.

Anticonvulsants, Sedatives, Relaxants

	Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/Province	Internal Supplier/Subsidiary?	Alternate Source?
A. 1.									
2.									
3.									
4.									
5.									
6.									
7.									
8.									
9.									
10.									
11.									
12.									
13.									
14.									
15.									

Anti-Inflammatories

	Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/Province	Internal Supplier/Subsidiary?	Alternate Source?
B. 1.									
2.									
3.									
4.									
5.									
6.									
7.									
8.									
9.									
10.									
11.									
12.									

13.									
14.									
15.									

Antileprosy

C.	Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/Province	Internal Supplier/Subsidiary?	Alternate Source?
	1.								
	2.								
	3.								
	4.								
	5.								
	6.								
	7.								
	8.								
	9.								
	10.								
	11.								
	12.								
	13.								
	14.								
	15.								

Antiprotozoals

D.	Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/Province	Internal Supplier/Subsidiary?	Alternate Source?
	1.								
	2.								
	3.								
	4.								
	5.								
	6.								
	7.								
	8.								
	9.								
	10.								
	11.								
	12.								
	13.								
	14.								
	15.								

Comments:

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 3.c Critical Commodities - Non-U.S. Suppliers

Identify any components, manufacturing materials, or finished products **provided by suppliers based outside the United States** that are critical to the final manufacture of the products identified in the previous section. Indicate the product area and product name(s) for which this component/material is required and the supplier's name and location. In addition, indicate whether the component/material is supplied by an internal company supplier/subsidiary or is supplied by an outside company. Finally, identify, to the best of your company's understanding, whether there is an alternate U.S.-based or non-U.S. based source available for each component/material.

Note: If your company does not manufacture a product in a particular product area, you may leave it blank.

Antivirals

	Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/Province	Internal Supplier/Subsidiary?	Alternate Source?
A. 1.									
2.									
3.									
4.									
5.									
6.									
7.									
8.									
9.									
10.									
11.									
12.									
13.									
14.									
15.									

Cancer Treatments

	Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/Province	Internal Supplier/Subsidiary?	Alternate Source?
B. 1.									
2.									
3.									
4.									
5.									
6.									
7.									
8.									
9.									
10.									
11.									
12.									

13.									
14.									
15.									

Cardiovasculars

C.	Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/Province	Internal Supplier/Subsidiary?	Alternate Source?
	1.								
	2.								
	3.								
	4.								
	5.								
	6.								
	7.								
	8.								
	9.								
	10.								
	11.								
	12.								
	13.								
	14.								
	15.								

Hormones

D.	Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/Province	Internal Supplier/Subsidiary?	Alternate Source?
	1.								
	2.								
	3.								
	4.								
	5.								
	6.								
	7.								
	8.								
	9.								
	10.								
	11.								
	12.								
	13.								
	14.								
	15.								

Comments:	
-----------	--

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 3.d Critical Commodities - Non-U.S. Suppliers

Identify any components, manufacturing materials, or finished products **provided by suppliers based outside the United States** that are critical to the final manufacture of the products identified in the previous section. Indicate the product area and product name(s) for which this component/material is required and the supplier's name and location. In addition, indicate whether the component/material is supplied by an internal company supplier/subsidiary or is supplied by an outside company. Finally, identify, to the best of your company's understanding, whether there is an alternate U.S.-based or non-U.S. based source available for each component/material.

Note: If your company does not manufacture a product in a particular product area, you may leave it blank.

Immunosuppressants

	Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/Province	Internal Supplier/Subsidiary?	Alternate Source?
A. 1.									
2.									
3.									
4.									
5.									
6.									
7.									
8.									
9.									
10.									
11.									
12.									
13.									
14.									
15.									

Stimulants

	Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/Province	Internal Supplier/Subsidiary?	Alternate Source?
B. 1.									
2.									
3.									
4.									
5.									
6.									
7.									
8.									
9.									
10.									
11.									
12.									

13.									
14.									
15.									

Vaccines

C.	Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/Province	Internal Supplier/Subsidiary?	Alternate Source?
	1.								
	2.								
	3.								
	4.								
	5.								
	6.								
	7.								
	8.								
	9.								
	10.								
	11.								
	12.								
	13.								
	14.								
	15.								

Other Products

D.	Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/Province	Internal Supplier/Subsidiary?	Alternate Source?
	1.								
	2.								
	3.								
	4.								
	5.								
	6.								
	7.								
	8.								
	9.								
	10.								
	11.								
	12.								
	13.								
	14.								
	15.								

Comments:	
-----------	--

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 3.e Critical Commodities - Non-U.S. Suppliers

Identify any components, manufacturing materials, or finished products **provided by suppliers based outside the United States** that are critical to the final manufacture of the products identified in the previous section. Indicate the product area and product name(s) for which this component/material is required and the supplier's name and location. In addition, indicate whether the component/material is supplied by an internal company supplier/subsidiary or is supplied by an outside company. Finally, identify, to the best of your company's understanding, whether there is an alternate U.S.-based or non-U.S. based source available for each component/material.

Note: If your company does not manufacture a product in a particular product area, you may leave it blank.

Surgical and Medical Equipment

	Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/Province	Internal Supplier/Subsidiary?	Alternate Source?
A. 1.									
2.									
3.									
4.									
5.									
6.									
7.									
8.									
9.									
10.									
11.									
12.									
13.									
14.									
15.									
16.									
17.									
18.									
19.									
20.									
21.									
22.									
23.									
24.									
25.									
26.									
27.									
28.									
29.									
30.									

Comments:

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 4.a

Critical Commodities - Utilization

Based on the products identified in the Section 2, indicate your company's manufacturing capacity utilization rate for each **product area** from 2007-2010. Indicate your company's maximum annual manufacturing capacity in units for 2009. In addition, using your company's 2010 production as a baseline, estimate the lead time required to increase production of each product area by the specified amount. For the purpose of this estimate, make the following assumptions:

- 1) Existing U.S. production facilities are to be operated at maximum practical productive capacity;
- 2) Labor availability reflects normal local market conditions;
- 3) Material availability reflects normal local market conditions; and
- 4) Facilities operate at the maximum rate possible given technological constraints.

Finally, from the drop-down list provided, select the primary factor that would prevent a production increase, if applicable.

Note: If your company does not manufacture a product in a particular product area, you may leave it blank.

Anaesthetics

	Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
		2007	2008	2009	2010	# of Units	Unit of Measure			
A. 1.										
A. 2.										
A. 3.										
A. 4.										
A. 5.										
A. 6.										
A. 7.										
A. 8.										
A. 9.										
A. 10.										

Analgesics

	Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
		2007	2008	2009	2010	# of Units	Unit of Measure			
B. 1.										
B. 2.										
B. 3.										
B. 4.										
B. 5.										
B. 6.										
B. 7.										
B. 8.										
B. 9.										
B. 10.										

Antibacterials										
	Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
		2007	2008	2009	2010	# of Units	Unit of Measure			
C.	1.									
	2.									
	3.									
	4.									
	5.									
	6.									
	7.									
	8.									
	9.									
	10.									
Antibiotics										
	Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
		2007	2008	2009	2010	# of Units	Unit of Measure			
D.	1.									
	2.									
	3.									
	4.									
	5.									
	6.									
	7.									
	8.									
	9.									
	10.									
Comments:										
BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act										

Section 4.b

Critical Commodities - Utilization

Based on the products identified in the Section 2, indicate your company's manufacturing capacity utilization rate for each **product area** from 2007-2010. Indicate your company's maximum annual manufacturing capacity in units for 2009. In addition, using your company's 2010 production as a baseline, estimate the lead time required to increase production of each product area by the specified amount. For the purpose of this estimate, make the following assumptions:

- 1) Existing U.S. production facilities are to be operated at maximum practical productive capacity;
- 2) Labor availability reflects normal local market conditions;
- 3) Material availability reflects normal local market conditions; and
- 4) Facilities operate at the maximum rate possible given technological constraints.

Finally, from the drop-down list provided, select the primary factor that would prevent a production increase, if applicable.

Note: If your company does not manufacture a product in a particular product area, you may leave it blank.

Anticonvulsants, Sedatives, Relaxants

	Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
		2007	2008	2009	2010	# of Units	Unit of Measure			
A. 1.										
A. 2.										
A. 3.										
A. 4.										
A. 5.										
A. 6.										
A. 7.										
A. 8.										
A. 9.										
A. 10.										

Anti-Inflammatories

	Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
		2007	2008	2009	2010	# of Units	Unit of Measure			
B. 1.										
B. 2.										
B. 3.										
B. 4.										
B. 5.										
B. 6.										
B. 7.										
B. 8.										
B. 9.										
B. 10.										

Antileprosy										
	Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
		2007	2008	2009	2010	# of Units	Unit of Measure			
C.	1.									
	2.									
	3.									
	4.									
	5.									
	6.									
	7.									
	8.									
	9.									
	10.									
Antiprotozoals										
	Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
		2007	2008	2009	2010	# of Units	Unit of Measure			
D.	1.									
	2.									
	3.									
	4.									
	5.									
	6.									
	7.									
	8.									
	9.									
	10.									
Comments:										
BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act										

Section 4.c

Critical Commodities - Utilization

Based on the products identified in the Section 2, indicate your company's manufacturing capacity utilization rate for each **product area** from 2007-2010. Indicate your company's maximum annual manufacturing capacity in units for 2009. In addition, using your company's 2010 production as a baseline, estimate the lead time required to increase production of each product area by the specified amount. For the purpose of this estimate, make the following assumptions:

- 1) Existing U.S. production facilities are to be operated at maximum practical productive capacity;
- 2) Labor availability reflects normal local market conditions;
- 3) Material availability reflects normal local market conditions; and
- 4) Facilities operate at the maximum rate possible given technological constraints.

Finally, from the drop-down list provided, select the primary factor that would prevent a production increase, if applicable.

Note: If your company does not manufacture a product in a particular product area, you may leave it blank.

Antivirals

	Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
		2007	2008	2009	2010	# of Units	Unit of Measure			
A.	1.									
	2.									
	3.									
	4.									
	5.									
	6.									
	7.									
	8.									
	9.									
	10.									

Cancer Treatments

	Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
		2007	2008	2009	2010	# of Units	Unit of Measure			
B.	1.									
	2.									
	3.									
	4.									
	5.									
	6.									
	7.									
	8.									
	9.									
	10.									

Cardiovasculars

C.	Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
		2007	2008	2009	2010	# of Units	Unit of Measure			
1.										
2.										
3.										
4.										
5.										
6.										
7.										
8.										
9.										
10.										

Hormones

D.	Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
		2007	2008	2009	2010	# of Units	Unit of Measure			
1.										
2.										
3.										
4.										
5.										
6.										
7.										
8.										
9.										
10.										

Comments:

--

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 4.d

Critical Commodities - Utilization

Based on the products identified in the Section 2, indicate your company's manufacturing capacity utilization rate for each **product area** from 2007-2010. Indicate your company's maximum annual manufacturing capacity in units for 2009. In addition, using your company's 2010 production as a baseline, estimate the lead time required to increase production of each product area by the specified amount. For the purpose of this estimate, make the following assumptions:

- 1) Existing U.S. production facilities are to be operated at maximum practical productive capacity;
- 2) Labor availability reflects normal local market conditions;
- 3) Material availability reflects normal local market conditions; and
- 4) Facilities operate at the maximum rate possible given technological constraints.

Finally, from the drop-down list provided, select the primary factor that would prevent a production increase, if applicable.

Note: If your company does not manufacture a product in a particular product area, you may leave it blank.

Immunosuppressants

	Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
		2007	2008	2009	2010	# of Units	Unit of Measure			
A. 1.										
A. 2.										
A. 3.										
A. 4.										
A. 5.										
A. 6.										
A. 7.										
A. 8.										
A. 9.										
A. 10.										

Stimulants

	Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
		2007	2008	2009	2010	# of Units	Unit of Measure			
B. 1.										
B. 2.										
B. 3.										
B. 4.										
B. 5.										
B. 6.										
B. 7.										
B. 8.										
B. 9.										
B. 10.										

Vaccines										
	Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
		2007	2008	2009	2010	# of Units	Unit of Measure			
C.	1.									
	2.									
	3.									
	4.									
	5.									
	6.									
	7.									
	8.									
	9.									
	10.									
Other Products										
	Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
		2007	2008	2009	2010	# of Units	Unit of Measure			
D.	1.									
	2.									
	3.									
	4.									
	5.									
	6.									
	7.									
	8.									
	9.									
	10.									
Comments:										
BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act										

Section 4.e Critical Commodities - Utilization

Based on the products identified in the Section 2, indicate your company's manufacturing capacity utilization rate for each **product area** from 2007-2010. Indicate your company's maximum annual manufacturing capacity in units for 2009. In addition, using your company's 2010 production as a baseline, estimate the lead time required to increase production of each product area by the specified amount. For the purpose of this estimate, make the following assumptions:

- 1) Existing U.S. production facilities are to be operated at maximum practical productive capacity;
- 2) Labor availability reflects normal local market conditions;
- 3) Material availability reflects normal local market conditions; and
- 4) Facilities operate at the maximum rate possible given technological constraints.

Finally, from the drop-down list provided, select the primary factor that would prevent a production increase, if applicable.

Note: If your company does not manufacture a product in a particular product area, you may leave it blank.

Surgical and Medical Instruments

	Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
		2007	2008	2009	2010	# of Units	Unit of Measure			
A. 1.										
2.										
3.										
4.										
5.										
6.										
7.										
8.										
9.										
10.										
11.										
12.										
13.										
14.										
15.										
16.										
17.										
18.										
19.										
20.										

Comments:

Section 5 Global Trade and Customer Distribution

If your company **imported** any health-related components, manufacturing materials, or finished products **from the list in Section 2** from 2007-2010, provide the HS-10 code used, a description of the product(s), and the total value of the imported commodities. If your company utilized more than ten HS codes, only identify the top ten by total import value.

Note: Harmonized Tariff Schedule (HTS) codes (10-digit) can be found at "HTS Online Resource Tool" located under "Research Tools" at <http://www.ustic.gov/index.htm>.

		HS-10 Code	Product Description(s)	2007-2010 Import Value
A.	1.			
	2.			
	3.			
	4.			
	5.			
	6.			
	7.			
	8.			
	9.			
	10.			

Indicate the percentage of your healthcare-related products that are sold in the United States to the following entities from 2007-2010:					
		2007	2008	2009	2010
B.	Hospitals				
	Ambulatory Services				
	Clinics				
	Pharmacies				
	Distributors/Wholesalers				
	State/Local Governments				
	Federal Government				
	Other (specify)				
	Other (specify)				
	Other (specify)				
Total (Must Equal 100%)		0%	0%	0%	0%

Comments: _____

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 6.a		Supplier Selection Criteria	
A.	Identify the top five criteria your company considers when selecting suppliers for healthcare-related components, manufacturing materials, and finished products.	Cost	
		Domestic Source	
		Non-U.S. Source	
		Product Packages (e.g., bundles of multiple products from the same supplier)	
		Delivery Logistics/Speed	
		Sole Supplier/Unique Products	
		Substitute for a Critical Product	
		Product Quality/Manufacturing Processes	
		Product Effectiveness (e.g., fewer side effects, higher success rate)	
		Product Availability	
		Terms of Payment	
		Other (specify)	
		Other (specify)	
Other (specify)			
B.	Does your company maintain long-term contracts with its suppliers? Explain below.		
	If 'Yes,' indicate how long, on average, these contracts last.		
Comments:			
BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act			

Section 6.b		Supplier Contracts	
A.	Does your company include "disruption clauses" in contracts with U.S.-based and non-U.S. based suppliers? If 'Yes,' explain the details of these clauses below (see the Definitions page for an explanation of disruption clauses).	U.S.-Based	Non-U.S. Based
B.	Does your company include "surge capacity provisions" in contracts with U.S.-based and non-U.S. based suppliers? If 'Yes,' explain the details of these clauses below (see the Definitions page for an explanation of surge capacity provisions).	U.S.-Based	Non-U.S. Based
C.	Does your company require production forecasting requirements in contracts with your suppliers? If 'Yes,' explain what these requirements entail below.		
D.	Has your company ever been a party to a rated order? A rated order is a prime contract, a subcontract, or a purchase order in support of an approved program issued in accordance with the provisions of the Defense Priorities and Allocations System (DPAS) regulation (15 CFR part 700). If 'Yes,' explain the details below.		
E.	Does your company have visibility into your suppliers' operations and inventory? If 'Yes,' identify what information your company has access to below.		
	Current production capacity	Identification of their suppliers	
	Company Certifications	Location of their suppliers	
	Maximum production capacity	Other (specify)	
	Inventory levels	Other (specify)	
	Raw material supplies	Other (specify)	
Comments:			
BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act			

Section 7.a		Inventory Information					
A.	Does your company maintain an inventory for healthcare-related components, manufacturing materials, and/or finished products?						
	On average, what is the normal supply level of finished, manufactured products normally kept in inventory?						
	On average, what is the normal supply level of components and manufacturing materials products normally kept in inventory?						
	If your company maintains an inventory of healthcare-related components, manufacturing materials, and/or finished products, explain how certain commodities are selected for inventory over others.						
<table border="1" style="width: 100%; height: 40px;"> <tr> <td colspan="4"></td> </tr> </table>							
B.	Does your company maintain a list of approved alternate supply sources for critical components, manufacturing materials, and/or finished products?						
C.	Does your company maintain relationships with multiple suppliers of the same product expressly as a contingency against supply disruptions? Explain your response.						
	<table border="1" style="width: 100%; height: 30px;"> <tr> <td colspan="3"></td> </tr> </table>						
D.	Does your company use or manufacture any critical components, manufacturing materials, or finished products that cannot be placed in inventory for any reason? If "Yes," identify the product, its use, and the reason why it cannot be placed in inventory.						
		Product	Product's Use	Reason It Cannot Be Placed in Inventory			
	1.						
	2.						
	3.						
	4.						
5.							
Comments:		<table border="1" style="width: 100%; height: 30px;"> <tr> <td colspan="2"></td> </tr> </table>					
BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act							

Section 7.b

Supply Disruptions and Shortages

Has your company had any significant supply disruptions or shortages for critical components, manufacturing materials, and/or finished products from 2007-2010?

If 'Yes,' identify the component/material/product, supplier, country, describe the issue, and detail how this product is used by your company.

	Component/Material/Product	Product Application	Supplier Name	Supplier Country	Disruption Duration (In Days)	Explanation of Supply Disruption
A. 1.						
2.						
3.						
4.						
5.						
6.						
7.						
8.						
9.						
10.						

B. Does your company foresee a potential risk of a supply disruption or shortages for critical components, manufacturing materials, and/or finished products in the near future? Explain your response.

C. Does your company believe that it is vulnerable to serious and/or prolonged supply chain disruptions? Explain your response.

D. Is your company taking steps to reduce its vulnerability to supply chain disruptions? Explain your response.

Comments:

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 7.c		Supply Disruptions and Shortages		
		From 2007-2010, has your company experienced a supply disruption as a result of a transportation problem? If "Yes," describe the incident(s) below, indicating the disruption duration and the effect on your company.		
		Incident Description	Duration (in days)	Effect on Company
A.	1.			
	2.			
	3.			
	4.			
	5.			
B.		Are there any U.S. Government regulations or processes that hinder your company's ability to maintain a secure, continuous supply chain? If 'Yes,' identify these regulations or processes below.		
C.		Are there any non-U.S. Government regulations or processes that hinder your company's ability to maintain a secure, continuous supply chain? If 'Yes,' identify these regulations or processes below.		
Comments:				
BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act				

Section 8		Cross-Sector Impacts	
A.	Are there any steps the U.S. government can take to reduce foreign dependency issues for healthcare-related products? Explain your answer.		
B.	Is your company taking any steps to reduce its exposure to foreign dependency issues? Explain your answer.		
C.	What factors does your company take into account when deciding to purchase and/or outsource overseas? Explain your answer.		
Comments:			
BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act			

Section 9.a**Financial Health**

Report select line items from your company's financial statement for years 2007-2010. From the drop-down indicate whether the reported income statement and balance sheet select line items are Business Unit/Division or Corporate/Whole Company financials.

Note: Business Unit/Division financials are preferred.

Note: Calendar year data is preferred.

Source of Financial Line Items:	
Reporting Schedule:	

Income Statement (Select Line Items)	Record in \$ Thousands, e.g. \$12,000.00 = survey input of \$12			
	2007	2008	2009	2010*
A. Net Sales (and other revenue)				
B. Cost of Goods Sold				
C. Total Operating Expenses				
D. Total Operating Income (Loss)				
E. Total Other Income (Expenses)				
F. Earnings Before Interest and Taxes				
G. Interest Expense				
H. Income Tax Expense				
I. Net Income				

Balance Sheet (Select Line Items)	Record in \$ Thousands, e.g. \$12,000.00 = survey input of \$12			
	2007	2008	2009	2010*
A. Cash				
B. Marketable Securities				
C. Accounts Receivable				
D. Inventories				
E. Total Current Assets				
F. Property, Plant, and Equipment				
G. Total Non-Current Assets				
H. Total Assets				
I. Accounts Payable				
J. Total Current Liabilities				
K. Long-Term Debt (less current portion)				
L. Total Non-Current Liabilities				
M. Total Liabilities				
N. Total Owner's Equity				

* If data is not available for 2010, please provide estimates.

Comments:	
-----------	--

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 9.b		Financial Health
Use the space below to qualify with narrative any anomalies, transactions, or non-recurring events reflected in your financial statement line items, e.g. reporting restatement, merger and acquisition, chapter 11, SEC investigation, etc.		
A.	2007	
B.	2008	
C.	2009	
D.	2010	
Comments:		
BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act		

Section 10 Certification	
The undersigned certifies that the information herein supplied in response to this questionnaire is complete and correct to the best of his/her knowledge. It is a criminal offense to willfully make a false statement or representation to any department or agency of the United States Government as to any matter within its jurisdiction (18 U.S.C.A. 1001 (1984 & SUPP. 1197))	
Company Name	
Company's Internet Address	
Name of Authorizing Official	
Title of Authorizing Official	
E-mail Address	
Phone Number and Extension	
Date Certified	
If POC is different from the above named, include below:	
Point of Contact Name	
Title of Point of Contact	
E-mail Address	
Phone Number and Extension	
Would you like a free copy of the final report?	
In the box below, please provide any additional comments or any other information you wish to include regarding this assessment.	
How many hours did it take to complete this survey?	
BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act	